Ezzedine K
Service de dermatologie, hôpital Henri-Mondor et EpiDermE, EA 7379, université Paris-Est Créteil Val-de-Marne, 94010, Créteil, France.
Ann Dermatol Venereol. 2016 Dec;143 Suppl 3:S37-S42. doi: 10.1016/S0151-9638(18)30048-6.
Over the last year there has been major publications related to therapeutic trials in infectious dermatology, not only with regard to Herpes zoster subunit vaccine but also for the treatment of uncomplicated abscesses or scabies. In addition, biological treatments continue to be on the forefront, not only in the treatment of psoriasis but also in other chronic inflammatory dermatologic diseases such as atopic dermatitis and hidradenitis suppurativa, two diseases that significantly impact quality of life and for which there are to date, few therapeutic alternatives in moderate to severe forms. In addition, the treatment of cyclin-resistant papulopustular rosacea was also the subject of a large French controlled randomized controlled trial that could modify our therapeutic approach by the use of isotretinoin. Finally, the prevention of rashes induced by erlotinib with oral doxycyline is also part of this 2016 "what's new in dermatological therapeutics".
在过去一年里,有许多关于感染性皮肤病治疗试验的重要出版物,不仅涉及带状疱疹亚单位疫苗,还包括单纯性脓肿或疥疮的治疗。此外,生物治疗仍然处于前沿,不仅用于治疗银屑病,还用于其他慢性炎症性皮肤病,如特应性皮炎和化脓性汗腺炎,这两种疾病对生活质量有显著影响,而对于中重度形式的疾病,目前几乎没有治疗选择。此外,对细胞周期蛋白抵抗性丘疹脓疱型玫瑰痤疮的治疗也是一项大型法国对照随机试验的主题,该试验可能会通过使用异维甲酸来改变我们的治疗方法。最后,口服强力霉素预防厄洛替尼引起的皮疹也是2016年“皮肤病治疗新进展”的一部分。